Sign In
Buy SYK
$337.03
+1.07 (+0.318%)
At Close: Aug 05, 2026
Dividend Champion, Contender, And Challenger Highlights: Week Of September 25
04:55am, Sunday, 25'th Sep 2022 Seeking Alpha
Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Click here to see companies with upcoming ex-dividend dates and pay dates.
Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod
03:41pm, Friday, 23'rd Sep 2022 Zacks Investment Research
Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.
Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod
12:47pm, Friday, 23'rd Sep 2022
Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.
3 Undervalued Dividend Champions With High Return Potential
02:29pm, Thursday, 22'nd Sep 2022
Income investors sometimes take the route of finding the best income stocks to meet their needs based upon criteria like dividend safety, dividend growth potential or historical dividend streak. These
The Zacks Analyst Blog Highlights Microsoft, Danaher, Raytheon Technologies, Stryker Corporation and Vale
10:38am, Thursday, 22'nd Sep 2022 Zacks Investment Research
Microsoft, Danaher, Raytheon Technologies, Stryker Corporation and Vale are included in this Analyst Blog.
Top Stock Reports for Microsoft, Danaher & Raytheon Technologies
05:50pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Danaher Corporation (DHR) and Raytheon Technologies Corporation (RTX).
Here's Why You Should Retain Stryker (SYK) Stock For Now
04:13pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Here's Why You Should Retain Stryker (SYK) Stock For Now
01:33pm, Wednesday, 21'st Sep 2022
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Diamon Hill CEO names a ‘mispriced’ medical technology stock
02:42pm, Tuesday, 20'th Sep 2022 Invezz
Stryker Corporation (NYSE: SYK) is a “mispriced” stock that has potential to offer lucrative returns over the long term, says Heather Brilliant. She’s the Chief Executive of Diamon Hill Capital
Diamon Hill CEO names a ‘mispriced' medical technology stock
10:42am, Tuesday, 20'th Sep 2022
Stryker Corporation (NYSE: SYK) is a “mispriced” stock that has potential to offer lucrative returns over the long term, says Heather Brilliant. She's the Chief Executive of Diamon Hill Capital Ma
There's always an opportunity to find mispriced stocks, says Diamond Hill CEO Heather Brilliant
09:24am, Tuesday, 20'th Sep 2022
Heather Brilliant, Diamond Hill Capital Management president and CEO, joins CNBC's 'Squawk Box' ahead of the open on Tuesday to break down potential investment opportunities.
Should You Buy Stryker Stock Around $225?
08:00am, Friday, 16'th Sep 2022
Stryker stock (NYSE: SYK), a medical devices company, has seen a 15% fall this year, in line with the broader S&P500 index, down 17%.
Piper Sandler Maintains Overweight Rating for Stryker: Here's What You Need To Know
04:17pm, Wednesday, 14'th Sep 2022 Benzinga
Piper Sandler has decided to maintain its Overweight rating of Stryker (NYSE:SYK) and raise its price target from $250.00 to $260.00.
Shares of Stryker are trading down 0.19% over the last 24 hours, a
Wells Fargo Slashes Price Target On This Stock By Over 71%, Also Check Out Other Major PT Changes Here
02:10pm, Wednesday, 14'th Sep 2022 Benzinga
Wells Fargo cut the price target on Cabaletta Bio, Inc. (NASDAQ: CABA) from $14 to $4. Wells Fargo analyst Derek Archila maintained the stock with an Overweight rating. Cabaletta Bio shares gained 0
Analyst Ratings for Stryker
05:34pm, Tuesday, 06'th Sep 2022 Benzinga
Within the last quarter, Stryker (NYSE:SYK) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
3
4
0
0
Last 30D
1
0
0
